Except for dapagliflozin 5 mg,empagliflozin 10 mg, sotagliflozin 200mg and sotagliflozin 400mg no risk of DKA was observed with SGLT2 inhibitors as an adjunct to insulin in the treatment of T1DM compared to insulin. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.